Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial

We aimed to investigate the efficacy, safety, and immunological activity of the anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody, tremelimumab, in advanced malignant mesothelioma

Luana CalabrĂ²


Scholarcy highlights

Need more features? Save interactive summary cards to your Scholarcy Library.